This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
Facts about Histone-lysine N-methyltransferase EHMT2.
Also mediates monomethylation of'Lys-56' of histone H3 (H3K56me1) at G1 phase, leading to encourage interaction between histone H3 and PCNA and regulating DNA replication. Also weakly methylates 'Lys-27' of histone H3 (H3K27me).
Human | |
---|---|
Gene Name: | EHMT2 |
Uniprot: | Q96KQ7 |
Entrez: | 10919 |
Belongs to: |
---|
class V-like SAM-binding methyltransferase superfamily |
ankyrin repeat-containing protein; BAT8; C6orf30; chromosome 6 open reading frame 30; DKFZp686H08213; EC 2.1.1.-; EC 2.1.1.43; EHMT2; euchromatic histone-lysine N-methyltransferase 2HLA-B-associated transcript 8; FLJ35547; G9A histone methyltransferase; G9a; G9AEm:AF134726.3; H3-K9-HMTase 3; Histone H3-K9 methyltransferase 3; histone-lysine N-methyltransferase, H3 lysine-9 specific 3; HLA-B associated transcript 8; KMT1CNG36/G9a; Lysine N-methyltransferase 1C; NG36; Protein G9a
Mass (kDA):
132.37 kDA
Human | |
---|---|
Location: | 6p21.33 |
Sequence: | 6; NC_000006.12 (31879759..31897698, complement) |
Expressed in all tissues examined, with high levels in fetal liver, thymus, lymph node, spleen and peripheral blood leukocytes and lower level in bone marrow.
Nucleus. Chromosome. Associates with euchromatic regions. Does not associate with heterochromatin.
This article reviews the Boster Bio Best Uses For The eHMT2 marker High-affinity primary antibodies and informationgraphics about genes. It also explains the benefits of Boster products, including their wide range of applications and samples. This article is applicable to scientists from all over the world. Boster products are available at any online retailer. You can also purchase Boster Bio Best Uses of the EHMT2 marker by submitting your results via their submission forms.
For over two decades, Boster Bio has specialized in the production of high-affinity, high-sensitivity antibodies. Boster Bio has spent more than two decades in perfecting its processes and technology. Their products are cited in more than 29,000 scientific publications and have been tested for use in IHC, WB, ELISA, Flow Cytometry, and other tests. No matter the reason that you require an antibody Boster Bio is sure to have the perfect antibody for your project.
For therapeutic purposes, Boster Bio scientists sought high-affinity hybridoma-derived mAbs that target hPC. These antibodies were obtained through a process called CDR humanization through grafting. Then, the key residues in murine FRs were back-mutated in order to restore full affinity. They were then modified using an alanine scanning mutational analysis (SSM) and saturated site-directed mutantagenesis to optimize the scFvs. The scFvs optimized for mutagenesis were transformed into full-length IgG and fusionbed using a modified IgG1 constant area.
One example of a highly-affinity antibody is the anti-beta actin monoclonal antibody from rabbits. It was developed by Boster this antibody was used for Western analysis to determine the retinol-binding protein 4 expression in porcine granulosa cells. Boster's handbooks on troubleshooting problems with immunoassays can be found at your disposal.
Primary antibodies are immunoglobulins produced by the host's immune system. They are vital components in numerous tests due to their specificity and affinity. They allow scientists to detect, purify and measure the target antibody. The quality of the primary antigen will determine the quality of the antibody. The more specific it is, the better the quality of its secondary antibodies. The more precise and specific it is for the research project, the more effective.
ELISA Titration is used to determine the specificity of each test bleed during antibody development. The most responsive animals are removed from their spleen cells. Hybridoma fusion is performed on the animals with the highest response. The positive supernatants are then subjected to a subcloning limit to ensure that all wells develop at the exact same rate. Once the antibodies are selected, they are tested for their potential use in disease models.
Using gene infographics, researchers have mapped the functions of genes in the human body, based on their expression in human cancer cells. The EHMT2 gene regulates several pathways that are essential to myogenic differentiation and growth. The EHMT2 gene is also involved in tumor progression. The RNA-Seq findings, which were incorporated into ChIP-Seq results reveal that EHMT2 regulates several genes involved in myogenic differentiation as well as cell cycle progression and metabolic pathways.
The team identified the molecular mechanisms that govern EHMT2 expression and functioning by using RNA-Seq. Cluster analysis was also performed on differentially expressed genes. The analysis revealed that 872 genes were significantly upregulated in siEHMT2-expressing cells (fold change greater than 1.2) and 695 genes were downregulated. Cell cycle progress and Wnt signaling are two of the top biological processes closely associated with siEHMT2 cell lines.
The EHMT1/2 protein promotes repair of DNA damages by recruiting BRCA1 53BP1, BRCA1, as well along with other factors associated with HR. The gene is often overexpressed and amplified by the ovarian cancer cells. The high level of expression of EHMT2 is associated with lower survival and aggressive metastatic peritoneal cancer. However more research is needed to explore its role in ovarian cancer.
The EHMT2 marker is associated with the survival rate of patients with BRC an uncommon and deadly blood cancer. This gene may also be linked to other genes. By analyzing gene expression levels across multiple cancer subtypes researchers are able to determine patients with increased EHMT2 expression. However, despite its predictive power, EHMT2 as a single biomarker for genes has its limitations. This article discusses the limitations of EHMT2 and the best way to reduce the number of genes contributing to a signature.
The qPCR technique was employed to examine the protein. Primers were designed to block EHMT2 transcription. The qPCR reaction was carried out in triplicate with at minimum two biological replicates. The primers for the EHMT2 gene were 5'-TCCGCCAAATGGCGGGAATGGAGAT-3' and MYOG-CAGTCTCAGTAAGTCAA-TTT-3' for each.
This study revealed that the EHMT2 gene is responsible for subcellular location and distribution of HSPD1. A phosphor array purchased from R&D Biosystems, was used for the analysis. The 200 ug of cell lysate contained the HSPD1 protein. The indicated antibodies were used to perform the Western blot and phosphor array. The results were compared with the levels of ACTB which is an intern control.
Breast cancer patients often have high levels of EHMT2 gene expression. EHMT2 is typically overexpressed within breast cancers when compared to normal breast cancer samples or liver samples. To determine whether EHMT2 is present in breast cancer, we compared the expression of EHMT2 to the FPKM values for normal liver and breast cancer (BRC tissue samples). The P-values were determined using Wilcoxon's tests.
The EHMT2 gene plays many important roles in cancer. It has been demonstrated to influence the growth of cancerous cells. In BRC, EHMT2 knockdown inhibits cell aggregation. It also reduces the formation of colonies in JR1 cells and RD cells. This study suggests that EHMT2 is a key indicator of prognosis. These findings are positive for treatment of BRC.
The mRNA expression levels of EHMT2 are linked to the development of tumors. The reduction of EHMT2 reduces the progression of tumors by increasing the signaling of Wnt. Furthermore, it enhances differentiation and reduces tumor progression. Studies have shown that inhibition of EHMT2 reduces the Wnt pathway and could lead to novel ERMS therapies.
PMID: 11707778 by Brown S.E., et al. Novel NG36/G9a gene products encoded within the human and mouse MHC class III regions.
PMID: 8457211 by Milner C.M., et al. The G9a gene in the human major histocompatibility complex encodes a novel protein containing ankyrin-like repeats.